Mesoblast schedules November 10 meeting while Mesoblast stock sits 45.33 percent below target

Published on 10/17/2026 at 20:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Target fell to AUD 3.64 on September 15, 2026. Mesoblast stock was last at EUR 1.19 on October 16, 2026, down 2.10 percent versus Tradegate close.

Company dates and valuation

Mesoblast announced its annual meeting date on October 13, 2026, with the meeting scheduled for November 10, 2026.
The average analyst target fell from AUD 3.93 to AUD 3.64 on September 15, 2026.
Mesoblast stock was last at EUR 1.19 at Tradegate on October 16, 2026, down 2.10 percent versus the Tradegate close.
Mesoblast had a market capitalization of AUD 2.6 billion and a trailing P/E of minus 31.16.

MESO, AU000000MSB8, Illustration mit AI erstellt.

Mesoblast scheduled its annual meeting for November 10, 2026, according to Simply Wall St in an update dated October 13, 2026. The average analyst target had fallen from AUD 3.93 to AUD 3.64 on September 15, 2026, leaving the new target 45.33 percent above the ASX price of AUD 1.99 on October 16, 2026. Mesoblast was last at EUR 1.19 at Tradegate on October 16, 2026, down 2.10 percent versus the Tradegate close.

Target remains above the ASX price

The target change gives investors a concrete valuation marker, but it does not remove the gap between the Australian quotation and the analyst estimate. Based on AUD 1.99, the AUD 3.64 target stands 82.91 percent above the stock price. The target is an average from three analysts, while the company remains loss-making on trailing figures.

Stock sits below its yearly high

The ASX quotation closed at AUD 1.99 on October 16, 2026, after rising 2.58 percent from AUD 1.94. Finance data placed the 52-week range at AUD 1.74 to AUD 3.31, putting the stock 39.88 percent below its high and 14.37 percent above its low. Trading volume reached 14,722,524 shares against an average of 2,740,977.

Valuation and November 10 date

Mesoblast had a market capitalization of AUD 2.6 billion and a trailing P/E of minus 31.16 on October 16, 2026. Its dividend yield was 0.00 percent. The annual meeting on November 10, 2026 is the next dated corporate event identified for shareholders, while the investor-relations calendar listed no further scheduled events.

Comparison with peers

Mesoblast (ASX, AUD): plus 2.58 percent, P/E minus 31.16, market capitalization AUD 2.6 billion

Telix Pharmaceuticals (ASX, AUD): plus 4.31 percent, P/E 122.70, market capitalization AUD 5.3 billion

BioNTech (Nasdaq, USD): minus 2.76 percent, P/E minus 11.57, market capitalization USD 22.0 billion

Price remains the daily frame

The euro quotation places the German trading perspective below the Australian price reference, while the analyst target and the November meeting provide the main dated markers. The comparison also shows different valuation profiles across biotechnology stocks, with Telix carrying a positive trailing multiple and BioNTech reporting a negative one.

The last available euro quotation was EUR 1.19 at Tradegate on October 16, 2026 at 6:37 p.m. CEST, down 2.10 percent versus the Tradegate close of October 16, 2026.